Growth factors and astrocytes metabolism: Possible roles for platelet derived growth factor

Medicinal Chemistry

Volumn 12, Issue 3, 2016, Pages 204-210

  Cabezas, Ricardo ^a   Avila Rodriguez, Marco ^a   Vega Vela, Nelson E ^a   Echeverria, Valentina ^b,c   González, Janneth ^a   Hidalgo, Oscar A ^a   Santos, Altair B ^d   Aliev, Gjumrakch ^e,f,g   Barreto, George E ^a,h  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^d UNIVERSIDADE ESTADUAL DO SUDOESTE DA BAHIA   (Brazil)

^e GALLY International Biomedical Research Consulting LLC   (United States)

^f University of Atlanta   (United States)

^g INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^h UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Astrocyte; Growth factors; Metabolism; Mitochondria; Neuroprotection; Platelet derived growth factor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SOMATOMEDIN; VASCULOTROPIN; VASCULOTROPIN B; WOUND HEALING PROMOTING AGENT;

ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CALCIUM METABOLISM; CELL METABOLISM; CELL PROTECTION; CELL VIABILITY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GLIAL PRECURSOR CELL; HUMAN; MITOCHONDRION; NERVE DEGENERATION; NEUROPROTECTION; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WOUND HEALING; ANIMAL; METABOLISM;

ANIMALS; ASTROCYTES; HUMANS; PLATELET-DERIVED GROWTH FACTOR;

EID: 84964758576     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411666151019120444     Document Type: Article

References (91)

1. Burkhalter, J.; Fiumelli, H.; Allaman, I.; Chatton, J.Y; Martin, J.L. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J. Neurosci., 2003, 23, 8212-8220.
2. Aberg, N.D.; Brywe, K.G.; Isgaard, J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. Scient. World J., 2006, 6, 53-80.
3. Mattson, M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N Y Acad. Sci., 2008, 1144, 97-112.
4. Yasuda, T.; Mochizuki, H. Use of growth factors for the treatment of Parkinson's disease. Expert Rev. Neurother., 2010, 10, 915-924.
5. Chen, L.W.; Horng, L.Y.; Wu, C.L.; Sung, H.C.; Wu, R.T. Activating mitochondrial regulator PGC-1a expression by astrocytic NGF is a therapeutic strategy for Huntington's disease. Neuropharmacology, 2012, 63, 719-732.
6. Genis, L.; Dávila, D.; Fernandez, S.; Pozo-Rodrigálvarez, A.; Martínez-Murillo, R.; Torres-Aleman, I. Astrocytes require insulinlike growth factor I to protect neurons against oxidative injury. F1000Res. 2014, 3, 28.
7. Yin, F.; Jiang, T.; Cadenas, E. Metabolic triad in brain aging: Mitochondria, insulin/IGF-1 signalling and JNK signalling. Biochem. Soc. Trans., 2013, 41, 101-105.
8. Andrae, J.; Gallini, R.; Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev., 2008, 22, 1276-1312.
9. Cabezas, R.; Avila, M.; Gonzalez, J.; El-Bachá, R.S.; Báez, E.; García-Segura, LM.; Jurado Coronel, J.C.; Capani, F.; Cardona- Gomez, G.P.; Barreto, G.E. Astrocytic modulation of blood brain barrier: Perspectives on Parkinson's disease. Front. Cell Neurosci., 2014, 8, 211.
10. Proschel, C.; Stripay, J.L.; Shih, C.H.; Munger, J.C.; Noble, M.D. Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons. EMBO Mol. Med., 2014, 6, 504-518.
11. Ramaswamy, S.; Kordower, J. Are growth factors the answer? Parkinsonism and related disorders. 2009, 15(Suppl 3), S176-S180.
12. Chen, Y.; Swanson, R.A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab., 2003, 23, 137-149.
13. Volterra, A.; Meldolesi, J. Astrocytes, from brain glue to communication elements: The revolution continues. Nat. Rev., 2005, 6, 626-640.
14. Chinta, S.; Andersen, J. Redox imbalance in parkinson. Biochim. Biophys. Acta, 2008, 1780, 1362-1367.
15. Hamby, M.E.; Sofroniew, M. Reactive Astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics, 2010, 7, 494-506.
16. Kimelberg, H.K.; Nedergaard, M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics, 2010, 7, 338- 353.
17. Parpura, V.; Grubisic, V.; Verkhratsky, A. Ca2+ sources for the exocytotic release of glutamate from astrocytes. Biochim. Biophys. Acta, 2011, 1813, 984-1018.
18. Halliday, G.M.; Stevens, C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord., 2011, 26, 6-17.
19. Oberheim, N.A.; Goldman, S.A.; Nedergaard, M. Heterogeneity of astrocytic form and function. Methods Mol. Biol., 2012, 814, 23-45.
20. Zonta, M.; Angulo, M.C.; Gobbo, S.; Rosengarten, B.; Hossmann, K.A.; Pozzan, T. Neuron- To- Astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci., 2003, 6, 43-50.
21. Maragakis, N.J.; Rothstein, J.D. Mechanisms of disease: Astrocytes in neurode generative disease. Nat. Clin. Pract. Neurol., 2006, 2, 679-689.
22. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
23. Barreto, G.; Veiga, S.; Azcoitia, I.; Garcia-Segura, L.M.; Garcia- Ovejero, D. Testosterone decreases reactive astroglia and reactive microglia after brain injury in male rats: Role of its metabolites, oestradiol and dihidrotestosterone. Eur. J. Neurosci., 2007, 25, 3039-3046.
24. Barreto, G.E.; Gonzalez, J.; Torres, Y.; Morales, L. Astrocyticneuronal crosstalk: implications for neuroprotection from brain injury. Neurosci. Res., 2011, 71, 107-113.
25. Kang, W.; Hebert, J.M. Signaling pathways in reactive astrocytes, a genetic perspective. Mol. Neurobiol., 2011, 43, 147-154.
26. Fitch, M.T.; Silver, J. CNS injury, glial scars and inflammation: inhibitory extracellular matrices and regeneration failure. Exp. Neurol., 2008, 209, 294-301.
27. Duffy, P.; Schmandke, A.; Schmandke, A.C.; Sigworth, J.; Shuh, N.; Cafferty, W. B. Rho- Associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J. Neurosci., 2009, 29, 15266-15276.
28. Zamanian, J.L.; Xu, L.; Foo, L.C.; Nouri, N.; Zhou, L. Genomic analysis of reactive astrogliosis. J. Neurosci., 2012, 32, 6391-6410.
29. Kanemaru, K.; Kubota, J.; Sekiya, H.; Hirose, K.; Okubo, Y.; Iino, M. Calcium-dependent N-cadherin up-regulation mediates reactive astrogliosis and neuroprotection after brain injury. Proc. Natl. Acad. Sci. U.S.A., 2013, 110, 11612-11617.
30. Itoh, N.; Ornitz, D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem., 2011, 149, 121-130.
31. Pang, Y.; Zheng, B.; Campbell, LR.; Fan, LW.; Cai, Z.; Rhodes, PG. IGF-1 can either protect against or increase LPS-induced damage in the developing rat brain. Pediatr. Res., 2010, 67, 579-584.
32. Sullivan, A.M.; Toulouse, A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine Growth Factor Rev., 2011, 22, 157-165.
33. Timmer, M.; Muller-Ostermeyer, F.; Kloth, V.; Winkler, C.; Grothe, C.; Nikkhah, G. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co- Transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms. Exp. Neurol., 2004, 187, 118-136.
34. Huang, B.; Krafft, P.R.; Ma, Q.; Rolland, W.B.; Caner, B.; Lekic. Fibroblast growth factors preserve blood-brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice. Neurobiol. Dis., 2012, 46, 204-214.
35. Peterson, A.L.; Nutt, J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics, 2008, 5, 270-280.
36. Gill, S.S.; Patel, N.K.; Hotton, G.R. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9, 589-595.
37. Markham, A.; Cameron, I.; Bains, R.; Franklin, P.; Kiss, J.P.; Schwendimann, L.; Gressens, P.; Spedding, M. Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. Eur. J. Neurosci., 2012, 35, 366-374.
38. Allen, S.J.; Watson, J.J.; Shoemark, D.K.; Barua, N.U.; Patel, N.K. GDNF, NGF, and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther., 2013, 138, 155-175.
39. Lee, H.; Pienaar, I.S. Disruption of the blood-brain barrier in Parkinson's disease: curse or route to a cure? Front. Biosci. (Landmark Ed.). 2014, 19, 272-280.
40. Sano, Y.; Shimizu, F.; Nakayama, H.; Abe, M.; Maeda, T.; Ohtsuki, S.; Terasaki, T.; Obinata, M.; Ueda, M.; Takahashi, R.; Kanda, T. Endothelial cells constituting blood nerve barrier have highly specialized characteristics as barrier-forming cells. Cell Struct. Funct., 2007, 32, 139-147.
41. Safi, R.; Gardaneh, M.; Panahi, Y.; Maghsoudi, N.; Zaefizadeh, M.; Gharib, E. Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J. Mol. Neurosci., 2012, 46, 654- 665.
42. Klein, P.; Müller-Rischart, A.K.; Motori, E.; Schönbauer, C.; Schnorrer, F.; Winklhofer, K.F.; Klein, R. Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO J., 2014, 33, 341-355.
43. Sofroniew, M.V.; Howe, C.L.; Mobley, W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci., 2001, 24, 1217e-1281e.
44. Geetha, T.; Rege, S.D.; Mathews, S.E.; Meakin, S.O.; White, M.F.; Babu, J.R. Nerve growth factor receptor TrkA, a new receptor in insulin signaling pathway in PC12 cells. J. Biol. Chem., 2013, 288, 23807-23813.
45. Clemmons, D.R. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol. Metab. Clin. North Am., 2012, 41, 425-443.
46. McDonald, T.J.; Nijland, M.J.; Nathanielsz, P.W.; The insulin-like growth factor system and the fetal brain: Effects of poor maternal nutrition. Rev. Endocr. Metab. Disord., 2007, 8, 71-84.
47. Zechariah, A.; Elali, A.; Doeppner, T.R.; Jin, F.; Hasan, M.R.; Helfrich, I. Vascular endothelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia and preserves the metabolic penumbra. Stroke, 2012, 44, 1690-1697.
48. Wright, G.L.; Maroulakou, I.G.; Eldridge, J.; Liby, T.L.; Sridharan, V.; Tsichlis, P.N.; Muise-Helmericks, R.C. VEGF stimulation of mitochondrial biogenesis: Requirement of AKT3 kinase. FASEB J., 2008, 22, 3264-3275.
49. Lladó, J.; Tolosa, L.; Olmos, G. Cellular and molecular mechanisms involved in the neuroprotective effects of VEGF on motoneurons. Front. Cell Neurosci., 2013, 7, 181.
50. Yu, J.; Ustach, C.; Kim, H.R. Platelet-derived growth factor signaling and human cancer. J. Biochem. Mol. Biol., 2003, 36, 49- 59.
51. Krupinski, J.; Issa, R.; Bujny, T.; Slevin, M.; Kumar, P.; Kumar, S.; Kaluza, J. A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke, 1997, 28, 564-573.
52. Fruttiger, M.; Calver, A.R.; Kruger, W.H.; Mudhar, H.S.; Michalovich, D.; Takakura, N.; Nishikawa, S.; Richardson, W.D. PDGF mediates a neuron- Astrocyte interaction in the developing retina. Neuron, 1996, 17, 1117-1131.
53. Bergers, G.; Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol., 2005, 7, 452-464.
54. Bonkowski, D.; Katyshev, V.; Balabanov, R.D.; Borisov, A.; Dore- Duffy, P. The CNS microvascular pericyte: Pericyte- Astrocyte crosstalk in the regulation of tissue survival. Fluids Barriers CNS., 2011, 8, 8.
55. Funa, K.; Sasahara, M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J. Neuroimmune Pharmacol., 2013, 9, 168-181.
56. Heldin, C.H.; Ostman, A.; Rönnstrand, L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta., 1998, 1378, F79-F113.
57. Heldin, C.H.; Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev., 1999, 79, 1283- 1316.
58. Fredriksson, L.; Li, H.; Eriksson, U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev., 2004, 15, 197-204.
59. Kazlauskas, A.; Cooper, J.A. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactionswith cell proteins. Cell, 1998, 58, 1121-1133.
60. Romashkova, J.A.; Makarov, S.S. NF-kappa B is a target of AKT in anti- Apoptotic PDGF signalling. Nature, 1999, 401, 86-90.
61. Shin, H.W.; Park, S.Y.; Lee, K.B.; Shin, E.; Nam, S.W.; Lee, J.Y.; Jang, J.J. Transcriptional profiling and Wnt signaling activation in proliferation of human hepatic stellate cells induced by PDGF-BB. Korean J. Hepatol., 2009, 15, 486-495.
62. Kang, S.W. Two axes in platelet-derived growth factor signaling: Tyrosine phosphorylation and reactive oxygen species. Cell. Mol. Life Sci., 2007, 64, 533-541.
63. Iqbal, S.; Zhang, S.; Driss, A.; Liu, Z.R.; Kim, H.R.; Wang, Y.; Ritenour, C.; Zhau, HE.; Kucuk, O.; Chung, L.W.; Wu, D. PDGF upregulates Mcl-1 through activation of betacatenin and HIF- 1alpha-dependent signaling in human prostate cancer cells. PLoS One, 2012, 7(1), e30764.
64. Wang, Z.; Ahmad, A.; Li, Y.; Kong, D.; Azmi, A.S.; Banerjee, S.; Sarkar, F.H. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta., 2010, 1806, 122-130.
65. Zhu, X.; Yao, H.; Peng, F.; Callen, S.; Buch, S. PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. Toxicol. Appl. Pharmacol., 2009, 240, 286-291.
66. Zheng, L.; Ishii, Y.; Tokunaga, A.; Hamashima, T.; Shen, J.; Zhao, Q.L. Neuroprotective effects of PDGF against oxidative stress and the signaling pathway involved. J. Neurosci. Res., 2010, 88, 1273- 1284.
67. Peng, F.; Yao, H.; Kaan, H.; Buch, S. Platelet-Derived Growth Factor CC-Mediated Neuroprotection against HIV Tat Involves TRPC-Mediated Inactivation of GSK 3beta. PLoS One, 2012, 7, e47572.
68. Nobes, C.D.; Hawkins, P.; Stephens, L.; Hall, A. Activation of the small GTP-binding proteins rho and rac by growth factor receptors. J. Cell Sci., 1995, 108, 225-233.
69. Li, L.; Li, J.; Wang, J.Y.; Yang, C.Q.; Jia, M.L.W.; Jiang, W. Role of RhoA in platelet-derived growth factor-BB-induced migration of rat hepatic stellate cells. Chin. Med. J., 2010, 123, 2502-2509.
70. Ball, S.G.; Shuttleworth, A.; York, C.M. Inhibition of platelet derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells, 2012, 30, 548-560.
71. Hedberg, K.M.; Bengtsson, T.; Safiejko-Mroczka, B.; Bell, P.B.; Lindroth, M PDGF and neomycin induce similar changes in the actin cytoskeleton in human fibroblasts. Cell. Motil. Cytoskeleton., 1993, 24, 139-149.
72. Ruusala, A.; Sundberg, C.; Arvidsson, A.K.; Rupp-Thuresson, E.; Heldin, C.H.; Claesson-Welsh, L. Platelet-derived growth factor (PDGF)-induced actin rearrangement is deregulated in cells expressing a mutant Y778F PDGF beta-receptor. J. Cell. Sci., 1998, 111(Pt 1), 111-120.
73. van Nieuw Amerongen, G.P.; Koolwijk, P.; Versteilen, A.; van Hinsbergh, V.V. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 211-217.
74. Simon, A.R.; Takajashi, S.; Fanburg, B.L.; Cochran, B.H. Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol., 2001, 282, L1296-L1304.
75. Thannickal, V.J.; Fanbourg, B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol., 2000, 279, L1005-L1028.
76. Cheng, B.; Mattson, M.P. PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: Evidence for induction of antioxidant pathways. J. Neurosci., 1995, 15, 7095- 7104.
77. Lehwald, N.; Tao, G.Z.; Jang, K.Y.; Papandreou, I.; Liu, B. bcatenin regulates hepatic mitochondrial function and energy balance in livers of mice. Gastroenterology, 2012, 143, 754-764.
78. Dejana, E. Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell Biol, 2004, 5, 261-270.
79. Tang, Z.; Arjunan, P.; Lee, C.; Li, Y.; Kumar, A.; Hou, X.; Wang, B.; Wardega, P.; Zhang, F.; Dong, L.; Zhang, Y.; Zhang, S.Z.; Ding, H.; Fariss, R.N.; Becker, K.G.; Lennartson, J . Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J. Exp. Med., 2010, 207, 867-880.
80. Gosslau, A.; Dittrich, W.; Willig, A.; Jaros, P.P. Cytological effects of platelet-derived growth factor on mitochondrial ultastructure in fibroblasts. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2001, 128(2), 241-249.
81. Salabei, J.K.; Hill, B.G. Mitochondrial fission induced by plateletderived growth factor regulates vascular smooth muscle cell bioenergetics and cell proliferation. Redox Biology, 2013, 1, 542-551.
82. Ridefelt, P.; Yokote, K.; Claesson-Welsh, L.; Siegbahn, A. PDGFBB triggered cytoplasmic calcium responses in cells with endogenous or stably transfected PDGF beta-receptors. Growth Factors, 1995, 12, 191-201.
83. Peng, F.; Yao, H.; Bai, X.; Zhu, X.; Reiner, BC. Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. J. Biol. Chem., 2010, 285, 21615-21624.
84. Cabezas, R.; Avila, M.F.; González, J.; El-Bachá, R.S.; Barreto, GE. PDGF-BB Protects Mitochondria from Rotenone in T98G Cells. Neurotox Res., 2015, 27(4), 355-67.
85. Aryal, M.; Arvanitis, C.D.; Alexander, P.M.; McDannold, N. Ultrasound- mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv. Drug Deliv. Rev., 2014, 72, 94-109.
86. Daneman, R. The blood-brain barrier in health and disease. Ann. Neurol., 2012, 72, 648-672.
87. Masserini, M. Nanoparticles for Brain Drug Delivery. ISRN Biochemistry, 2013, 2013, 1-18.
88. McDannold, N.; Vykhodtseva, N.; Jolesz, F.A.; Hynynen, K. MRI investigation of the threshold for thermally induced blood-brain barrier disruption and brain tissue damage in the rabbit brain. Magn. Reson. Med., 2004, 51, 913-923.
89. Arena, C.B.; Garcia, P.A.; Sano, M.B.; Olson, J.D.; Rogers- Cotrone, T.; Rossmeisl, J.H.; Davalos, R.V. Focal blood-brainbarrier disruption with high frequency pulsed electric fields. Technology, 2014, 02, 206.
90. Hauser, R.A. Future treatments for Parkinsons disease: surfing the PD pipeline. Int. J. Neurosci., 2011, 121(Suppl. 2), 53-62.
91. Jankovic, J.; Poewe, W. Therapies in Parkinson's disease. Curr. Opin. Neurol., 2012, 25, 433-447.